Together, iCAD and Karolinska plan to develop an AI breast cancer risk assessment model geared toward commercial use, with the expectation of entering an exclusive license agreement upon its completion. Development of the new model will stem from a prior breast cancer risk-prediction model that the Karolinska researchers developed using mammography data provided by iCAD's AI cancer detection software.
"Our research using the iCAD AI technology has shown that by simply using the information available in the mammogram images, we can more accurately stratify women based on short-term risk," Dr. Per Hall of Karolinska said in a statement.
In a Friday presentation at ECR 2019 in Vienna, Hall will discuss the institute and iCAD's collaborative approach to paving the way for risk-stratified breast cancer screening.